A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522723-98-00

Enrollment

Registered

2026-06-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid tumor

Brief summary

Frequency, severity, and relatedness of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Detailed description

Incidence of Dose-Limiting Toxicity (DLT) by dose cohorts, Assessment of the objective response rate (ORR), complete response (CR), clinical benefit rate (CBR), duration of response (DOR), time to response (TTR), progression free survival (PFS), and overall survival (OS)

Interventions

DRUGDOCETAXEL

DRUGKB707

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Frequency, severity, and relatedness of Adverse Events (AEs) and Serious Adverse Events (SAEs)	—

Secondary

Measure	Time frame
Incidence of Dose-Limiting Toxicity (DLT) by dose cohorts, Assessment of the objective response rate (ORR), complete response (CR), clinical benefit rate (CBR), duration of response (DOR), time to response (TTR), progression free survival (PFS), and overall survival (OS)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 1, 2026